Compare Alcon AG (ALC) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Levi Strauss & Co. — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Levi Strauss & Co. trades at $24.49 (market cap $9.48B). The key difference: Alcon AG is far larger — about 3.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| ALC | LEVI | |
|---|---|---|
Market Cap | $32.69B | $9.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $24.83 |
52-Week Low | $62.02 | $17.92 |
Enterprise Value | $36.28B | $10.99B |
Dividend Yield | 0.54% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Levi Strauss (LEVI) trades at $24.66, up 1.02% with bullish technical indicators and strong earnings momentum after three consecutive quarterly beats. The company demonstrates robust profitability with a 61.69% gross margin and 9.52% net margin, supported by a $29.00 analyst consensus price target representing 17.6% upside. Recent news highlights Q2 2026 earnings anticipation and strategic focus on women's apparel expansion.
Outlook remains positive with earnings growth and dividend stability, though risks include inflationary pressures and competitive retail dynamics. The stock's current valuation at 18.15x P/E appears reasonable given 29.19% ROE, but investors should monitor Q2 results on July 8 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
